Platinum drug effects on the expression of genes in the polyamine pathway: Time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 711-723

  Varma, Ram ^a   Hector, Suzanne ^a   Greco, William R ^a   Clark, Kimberly ^a   Hawthorn, Lesleyann ^a   Porter, Carl ^a   Pendyala, Lakshmi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Gene expression profiling; Oxaliplatin; Platinum; Polyamines

Indexed keywords

CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; POLYAMINE;

ARTICLE; BIOSYNTHESIS; CANCER CELL CULTURE; DATA ANALYSIS; DOWN REGULATION; DRUG EFFECT; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; MATHEMATICAL MODEL; ORNITHINE DECARBOXYLASE GENE; OVARY CARCINOMA; POLYAMINE METABOLISM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; S ADENOSYLMETHIONINE DECARBOXYLASE GENE; SPERMIDINE SYNTHASE GENE; STATISTICAL MODEL;

ACYLTRANSFERASES; ANTINEOPLASTIC AGENTS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; METABOLISM; MODELS, THEORETICAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYAMINES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33947320115     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0325-3     Document Type: Article

References (36)

1. Abeloff MD, Rosen ST, Luk GD, Baylin SB, Zeltzman M, Sjoerdsma A (1986) Phase II trials of α-difluoromethylornithine, an inhibitor of polyamine synthesis in advanced small cell lung cancer and colon cancer. Cancer Treat Rep 70:843
2. Almon RR, Dubois DC, Jin JY, Jusko WJ (2005) Pharmacogenomic responses of rat liver to methylprednisolone: an approach to mining a rich microarray time series. AAPS J 7:E156-E194
3. Almon RR, Lai W, Dubois DC, Jusko WJ (2005) Corticosteroid-regulated genes in rat kidney: mining time series array data. Am J Physiol Endocrinol Metab 289:E870-E882
4. Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 10:1663-1682
5. Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R (1999) Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clinical Cancer Research 5:2035-2041
6. Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R (1999) Prgnostic value of ornithine decarboxylase and polyamines in human breast cancer: correlations with clinicopathological parameters. Clin Cancer Res 5:2035-2041
7. 1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. Can Res 49:3829-3833
8. 1- acetyltransferase. Mol Pharm 64:1153-1159
9. Chen Y, Kramer DL, Li F, Porter CW (2003) Loss of inhibitor of apoptosis proteins as a determinant of polyamine-analogue-induced apoptosis in human melanoma cells. Oncogene 22:4964-4972
10. Devereux W, Wang Y, Stewart TM, Hacker A, Smith R, Frydman B, Valasinas AL, Reddy VK, Marton LJ, Ward TD, Woster PM, Casero RA (2003) Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother Pharmacol 52:383-390
11. Di Francesco AM, Riccardi R (2002) Cellular and molecular aspects of the drugs of the future. Cell Mol Life Sci 59:1914-1927
12. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868
13. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406
14. Hector S, Hawthorn L, Greco W, Pendyala L (2002) Gene expression profiles after oxaliplatin treatment in A2780 ovarian carcinoma cells. Proc AACR 43:62
15. 1-acetylransferase. Mol Cancer Ther 3:813-822
16. Kahana C, Asher G, Shaul Y (2005) Mechanisms of protein degradation. An odyssey with ODC. Cell Cycle 4:1461-1464
17. Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW (1999) Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Can Res 59:1278-1286
18. Levasseur LM, Slocum HK, Rustum YM, Greco WR (1998) Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Res 58:5749-5761
19. Libby PR, Henderson M, Bergeron RJ, Porter CW (1989) Major increases in spermidine/spermine-N1-acetyltransferase activity by spermine analogues and their relationship to polyamine depletion and growth inhibition in L1210 cells. Cancer Res 49:6226-6231
20. Mangold U (2005) The antizyme family: polyamines and beyond. IUBMB Life 57:671-676
21. Mohan RR, Challa A, Gupta S, Bostwick DG, Ahmad N, Agarwal R, Marengo SR, Amini SB, Paras F, MacLennan GT, Resnick MI, Mukhtar H (1999) Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 5:143-147
22. Porter C, Herrera-Omelas L, Pera P, Petrelli NF, Mittleman A (1987) Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 60:1275-1281
23. Porter CW, Bernacki RJ, Miller J, Bergeron RJ (1993) Antitumor activity of N1,N11-bis(ethyl)norspermine against human melanoma xenografts and possible biochemical correlates of drug action. Can Res 53:581-586
24. 1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 51:3715-3720
25. Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, et al (1990) Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Nat Cancer Inst 82:1113-1118
26. Scalabrino G, Ferioli ME (1985) Degree of enhancement of polyamine biosynthetic decarboxylase activities in human tumors: A useful new index of degree of malignancy. Cancer Detect Prev 8:11
27. 12-bis(ethyl)- spermine, on polyamine metabolism and cell growth in human melanoma cell lines and melanocytes. Anticancer Res 12:1083-1089
28. Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapetic applications. Cell Mol Life Sci 58:244-258
29. Thomas T, Balabhadrapathruni S, Gallo MA, Thomas TJ (2002) Development of polyamine analogs as cancer therapeutic agents. [Review]. Oncol Res 13:123-135
30. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. [erratum appears in Proc Natl Acad Sci USA 2001 98(18):10515]. Proc Natl Acad Sci USA 98:5116-5121
31. Urdiales JL, Medina MA, Sanchez-Jimenez F (2001) Polyamine metabolism revisited. Eur J Gastroenter 13:1015-1019
32. Varma R, Hector S, Pendyala L, Greco WR (2005) Modeling and analysis of drug concentration-effect and time course patterns in gene expression data from microarray experiments. Proc AACR 46:2
33. Varma RR, Hector S, Clark K, Greco WR, Hawthorn L, Pendyala L (2005) Gene expression profiling of a clonal isolate of oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 14:925-932
34. Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW (2002) Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 367:665-675
35. 1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319-38328
36. Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW (2003) Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion. Biochem J 370:19-28